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NANOSTRUCTURAL CONTROL OF IMPLANTABLE
XEROGELS FOR THE CONTROLLED RELEASE OF
BIOMOLECULES
SHULA RADIN AND PAUL DUCHEYNE
Department of Bioengineering
Center for Bioactive Materials and Tissue Engineering
University of Pennsylvania

Introduction
Controlled release systems are designed to deliver controlled amounts of
therapeutic agents to specific target sites over extended duration of time. The local
delivery eliminates the risks of side effects associated with oral or parenteral therapies
such as systemic toxicity. It also improves the efficacy of the treatment by achieving
higher drug concentrations at the target site than are possible with systemic
administration. In order to avoid the need for a second operation, resorbable and
biocompatible materials are very desirable for topical applications during surgery. In
response to the need for such carriers, biodegradable polymers have been proposed [1-6].
However, it has been reported that the degradation of polymers, which is the mechanism
controlling the release of bioactive molecules, can cause an inflammatory response that
interferes with the intended therapy [6-9]. Demineralized bone matrix, synthetic bioactive
ceramics and glass-ceramics have also been considered as implantable controlled release
materials.10-16 These materials are biocompatible and can enhance bone healing.

However, these macroporous materials usually demonstrate a poorly controlled “burst”
release profile; that is, the release is largely terminated shortly after implantation. For
effective healing, however, it is desirable to release an initial large concentration of drugs
post-operatively, followed by a steady long-term release.
Sol-gel processed materials represent an alternative to the materials previously
used for the controlled release of biologically active agents [17]. Room-temperature
processed sol-gel derived silicas (also called xerogels) have been explored for various
biomedical applications. Base-catalyzed or two-step acid-base-catalyzed xerogels have
been used for the encapsulation of enzymes, cells and living tissues [18-20]. Acidcatalyzed xerogels have been studied as controlled release materials [21-28]. A simple
room-temperature process can be used for the incorporation of various biological
molecules into silica xerogels. This room-temperature process provides easily
reproducible xerogel properties. Large quantities of biological agents can be added and
uniformly distributed in the liquid sol. After gelation, condensation and drying, the agents
become encapsulated in a glassy solid. These materials are resorbable, highly porous and
nanostructured (pore size from 1 to 5 nm). Their structural properties can be extensively
controlled by altering sol-gel processing parameters (such as selection of silica
precursors, the use of additional oxides, catalysts, solvents, pH of sol, water/alkoxide
molar ratio, temperature and conditions of condensation and drying) [17].
In our laboratory, we have studied room temperature processed silica xerogels
for controlled release of various biological agents such as drugs, proteins and growth
factors. [22-25] In vitro, we studied the effect of synthesis parameters on the structure
and the release properties of xerogels. In vivo, we assessed silica xerogels as resorbable

and biocompatible materials [26]. In this paper, we summarize these in vitro and in vivo
studies of silica xerogel controlled released materials.

Synthesis of silica xerogels with incorporation of biologically active molecules –
methods
The chemical reactions that take place during the synthesis of silica gels include
hydrolysis and condensation reactions. The hydrolysis reaction, which can be either acid
or base catalyzed, replaces alkoxide groups with hydroxyl groups. Siloxane bonds (Si-OSi) are formed during subsequent condensation. Alcohol and water are byproducts of the
condensation reaction and evaporate during drying. Theoretically, the overall reaction is
as follows [17]:
n Si(OR)4 + 2n H2 O → n SiO2 + 4n ROH
However, in reality, the completion of the reaction and the chemical composition of the
resulting product depend on the excess of water above the stoichiometric H2O/Si ratio of
2. A number of other sol-gel processing parameters (such as pH of the sol, type and
concentration of solvents, temperature, aging and drying schedules, etc.) can also affect
the composition, structure, and properties of the resulting product.
In our studies, various biological molecules having different size were used for
incorporation into silica xerogels. These included drugs such as naltrexone (0.4 kDa) and
the antibiotic vancomycin (3 kDa) and macromolecules such as trypsin inhibitor (20 kDa)
and TGF-β (22 kDa) [22-25].
All xerogels were synthesized by a room temperature process using silica
precursors such as tetramethoxysilane (TMOS) or tetraethoxysilane (TEOS). In general,

the procedure was as follows: single-step acid-catalyzed hydrolysis (pH 2.0–3.0) with
excess of water over the stoichiometric H2O/Si ratio was used. TMOS (or TEOS),
deionized (DI) water and acid were mixed in a glass beaker and stirred using a magnetic
stirrer to obtain a homogenous sol. HCl or glacial acetic acids were used as catalysts for
the hydrolysis of TMOS and TEOS, respectively. Then molecules of interest were then
dissolved in DI and added to the sol. Upon mixing, the sol was cast into cylindrical
polystyrene vials. The vials were sealed and the sol samples were allowed to gel and age.
Subsequently, the vials were opened, and the gels were allowed to dry until the gel
weight became constant.
Using the basic single-step acid catalyzed process, a number of processing
parameters was varied to determine the effects on the nanostructure and release properties
of the xerogels. These included variations in pH, solvents, water/alkoxide molar ratio,
and aging and drying schedule. Modifications of the sol-gel process included the use of
organic or organomodified alkoxysilane. Parametrical changes also included variations in
concentrations of incorporated bioactive molecules.

Characterization of xerogel nanostructure
Fourier Transform Infrared (FTIR) spectrometry (5 DXC, Nicolet, Madison,
WI) and gas (nitrogen) sorption analysis (Autosorb 1, Quantachrome) were used for the
xerogel characterization. FTIR analysis was performed using the diffuse reflectance
mode. Prior to obtaining nitrogen adsorption-desorption isotherms the samples were
outgassed at 350C for 48 hours. Multi-point BET [29] was used to determine the surface
area (SA), pore volume (PV) and mean pore radius (PR).

FTIR spectra of xerogels (not shown) were typical for acid-catalyzed silica
xerogels [17]. The FTIR analysis showed that the xerogels were well hydrolyzed and
polymerized [24]. The incorporation of bioactive molecules did not produce any
discernible effect on the FTIR spectra of xerogels [24].
Nitrogen adsorption-desorption isotherms of all acid-catalyzed silica xerogels
studied were typical for a Type I isotherm (BDDT classification [30]) [24]. This isotherm
type is characteristic of a microporous solid, i.e. a solid with a large number of pores
having radii equal to or below 1.5 nm. Variation of the processing parameters (which
included the use of methanol as a solvent, pH (from 1 to 5), water/alkoxide ratio (from 4
to 10), aging time (from 1 to 14 days), and drying schedule)) did not affect the isotherm
type. The isotherms of xerogels containing bioactive molecules such as naltrexone,
vancomycin and trypsin inhibitor were also characteristic of a microporous solid.
Physical properties of xerogels such as pore volume, BET surface area, and mean
pore radius were derived from the isotherm analysis. Variations in nanostructures of
xerogels with water/TMOS ratio and biomolecule load are shown in Tables 1 and 2,
respectively.

Table 1. The effect of water/TMOS molar ratio on the surface area (SA), pore volume (PV) and pore
radius (PR) of silica xerogels.

Ratio

PV, cc/g
PR, nm
SA, m2/g
4
519
0.21
6
761
0.31
10
822
0.35

0.9
0.92
0.93

Table 2. The effect of incorporation of vancomycin (V) and trypsin inhibitor (TI) on the physical
properties of silica xerogels

Load/sample
1 mg V
10 mg V
2 mg TI

SA, m2/g
PV, cc/g
PR, nm
868
0.39
936
0.48
845
n/d

0.98
1.04
0.96

• n/d: not determined
• vancomycin load/ sample of 1 and 10 mg correspond to 1.1 and 11 mg/g concentration;
• trypsin inhibitor load of 2 mg corresponds to 6 mg/g concentration.

As shown in Table 1, variation of the water/TMOS ratio does not affect the pore
size: PR of xerogels with the ratio of 4, 6 or 10 was about 0.9 nm. However, this variation
largely affects the surface area (SA) and pore volume (PV): there is a major reduction in
the SA and in the PV values with a decrease of the ratio from 10 to 4.
Concerning the incorporation of bioactive molecules, the presence of vancomycin or
trypsin inhibitor did not produce a significant effect on the physical properties of xerogels
(Table 2). The effect of other parametrical variations (such as the use of methanol as a
solvent, changes in pH from 1 to 5, and variations in the aging and drying schedule) was
not significant either.
Therefore, it was found that the nanoporosity of xerogels could be varied to a large
degree by altering the synthesis parameters such as the water/alkoxide molar ratio.

Controlled release of drugs and proteins from silica xerogels
Xerogels with various concentrations of drugs (naltrexone or vancomycin) or
proteins (trypsin inhibitor), were used in the vitro release study. Xerogels with naltrexone
were TEOS-derived, while those with vancomycin or trypsin inhibitor were TMOSderived. Naltrexone was incorporated in xerogel with a water/alkoxide ratio of 6 (R6

xerogel), whereas vancomycin and the trypsin inhibitor were incorporated in R10
xerogels. Xerogel samples used for the study were shaped either as discs or granules. The
elution studies were conducted in tris buffered simulated physiological solution (SPS, pH
7.3 at 370C) and solutions were exchanged daily. The ratio of each specimen weight to
solution volume was large enough to reach solution saturation with Si-species shortly
after immersion and thereby prevent degradation of the samples by dissolution [31]. The
immersed samples were maintained in a water-jacketed incubator at 370C.
The released concentrations of naltrexone and vancomycin were measured using
a UV-visible spectrophotometer (Ultrospec Plus, Pharmacia LKB) at 283 and 280 nm,
respectively. A gold colloidal assay (Integrated Separation Systems) was used for the
determination of concentrations of trypsin inhibitor. Wet chemical analysis (atomic
absorption spectrophotometry, Perkin-Elmer 5100 PC, Norwalk, CT) was used to
confirm that solution saturation with Si-concentrations was reached within minutes after
immersion of xerogel samples .

Controlled release of drugs (naltrexone and vancomycin)
As shown in Figure 1, a sustained release of naltrexone was observed over 12
days. In this figure, the mean cumulative release of naltrexone from R6 xerogels is
plotted as a function of elution time and load (3, 6 and 9 mg/sample), The data also
demonstrate that the release rate and the amount released were load-dependent. However,
the total recovered percentage did not depend on the load and was about 80% for the
various load groups.
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Figure 1. Cumulative release of naltrexone from TEOS-derived xerogel as a function of elution time and load.
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Figure 2. Cumulative release of vancomycin from TMOS-derived xerogel as a function of elution time and load.

The data in Figure 2 demonstrate that the release of vancomycin from R6
xerogels, loaded with 10, 20 or 30 mg/g, was also a controlled, load-dependent, long-term
release. The release rates (determined at the linear portions of the release profiles) were
12.4, 21.6, and 34.2 µg/h for the 10-, 20-, and 30-mg/g groups, respectively. These values
of hourly release greatly exceeded the minimum inhibitory concentration (MIC) of
vancomycin for Gram-positive bacteria (4 µg/ml [32]). By 14 days of immersion, the
total release from the 10-mg/g xerogel was about 80% of the original vancomycin load,
whereas about 90% was released from 20- and 30-mg/g xerogels.
The possible mechanism of release can be ascertained by presenting the release
data as a function of the square root of time [21,23]. Cumulative release of vancomycin
from R10 xerogel is presented this way in Figure 3.
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Figure 3. Cumulative release of vancomycin from TMOS-derived R10 xerogel as a function of the square root
of time and load.

The linearity of the release plots versus the square root of time reveals first-order release
kinetics. As determined by regression analysis, there was no delay and no “burst” in the
vancomycin release. Similar presentation of the cumulative release of naltrexone also
revealed first-order release without any delay or “burst”.
It is well-known that the release which is proportional to the square root of time
results from a diffusion driven process. The Highuchi equation relates the total amount of
drug released via diffusion from a porous solid matrix into a medium acting as a perfect
sink [33]:
Q = [(Dε/τ ) ⋅ (2A – εCs) ⋅ (Cst)]1/2 (1)
where Q is the amount of drug released per unit exposed area after time t, D is the
diffusivity of the drug in the permeating fluid, τ is the tortuosity factor of the capillary
channel network, A is the total amount of drug present in the matrix per unit volume, Cs is
the solubility of the drug in the permeating fluid, and ε is the porosity of the matrix.
The first-order release kinetics of both naltrexone and vancomycin (from R6 and
R10 xerogels, respectively) suggests a diffusive mechanism. The model also suggests that
the release kinetics depend on the total amount of the drug in the porous matrix. The
load-dependent release kinetics of naltrexone and vancomycin agree with the model.

Controlled release of model protein (trypsin inhibitor)
The mean cumulative release of trypsin inhibitor (TI) from R10 xerogels loaded
with 2, 5, and 10 mg/sample as a function of elution time is given in Figure 4. The data
show a sustained release of TI over a long-term elution period, up to 63 days (9 weeks).
Similarly to the release of smaller drug molecules, the release rate of TI and the amount

released were load-dependent. However, in contrast to smaller molecules, the TI release
was significantly slower. The total release of vancomycin was about 90% by three weeks,
whereas only 7, 20 and 15% of TI was released by this time from the 2, 5 and 10 mg load
groups, respectively. Also, the pattern of TI release was different from that of the smaller
molecules. The first-order release of both naltrexone and vancomycin occurred without
any delay, whereas a significant delay in the TI release was revealed by plotting the data
against the square root of time [23]. This delay was load-dependent: 24 or 100 hours for
the 10 or 2 mg load groups, respectively. This initial delay was followed by first-order
release. By 9 weeks, the total recovery was 21, 43 and 32% for the 2, 5 and 10 mg load
groups, respectively.
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Figure 4. Cumulative release of trypsin inhibitor from TMOS-derived xerogel as a function of elution time and
load.

Nanostructural control of release properties
The effect of xerogel nanostructure on the release properties was studied by
using xerogels with various water/TMOS molar ratios. As shown in Table 1, variations
in the ratio affect the surface area and the pore volume of xerogels without changing their
pore size.
Xerogels with the ratio of 4, 6, and 10 (R4, R6, and R10 xerogels) and
vancomycin load of 20 mg/g were used. The data in Figure 5 demonstrate a major effect
of the ratio on the kinetics of vancomycin release.
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Figure 5. Percent of vancomycin released from TMOS-derived 20-mg/g xerogel as a function of elution time
and water/TMOS ratio (R).

The release rates decreased with a decrease in the ratio: the rates of 21.6, 12.2, and 5 µg/h
were observed for the R10, R6, and R4 xerogels, respectively (the rates for R10 and R6
xerogels were determined at the linear portions of the plots). About 90% of the
vancomycin load was released from R10 and R6 xerogels by 14 and 21 days,
respectively. In comparison, only 28% of the load was released from R4 xerogels by 21
days of immersion. Variations in the ratio produced not only a change in the kinetics of
release, but also a complete change in the pattern of release. The release from R10 and
R6 xerogels was characterized by a first-order release followed by slower, steady release.
In comparison, the release from R4 xerogel was a steady, near-zero-order release. This
change from a first-order release to a near-zero-order release suggests a change from a
diffusion-controlled process to a surface-controlled process.
The observed effect of the water/alkoxide ratio on the release properties is
associated with changes in the surface area (SA) and pore volume (PV) (Table 1). In fact,
R10 and R6 xerogels with SA above 750 cm2 and PV greater than 0.32 cc/g, showed a
first-order release and a high drug recovery. A major reduction in the SA and PV of R4
xerogels resulted in a major change in the release kinetics of Vancomycin: a slower, zeroorder release was observed. These observations suggest a correlation between the
porosity of xerogels and the release kinetics. Such a correlation is in agreement with the
Highuchi model for the release of a drug from a porous matrix, where the porosity along

with other parameters, such as the solubility, diffusivity, and the amount of the drug in
the matrix, affect the release kinetics.
The findings of this study suggest that the long-term release properties of silica
xerogels can be tailored via nanostructural control. Desirable structural properties can be
selected in view of therapeutic requirements. Control of the structural properties via solgel processing is simple and does not produce any adverse effect on the biological
activity of the therapeutic agents.
Biological activity of agents released from silica xerogel: Bactericidal efficacy assay
of released vancomycin
Vancomycin is the most effective antibiotic against Gram-positive bacteria such
as Staphylococci and Streptococci [32]. The bactericidal efficacy (inhibition of
Staphylococcus aureus growth) of vancomycin released from the xerogel samples, was
assayed according to the standard disc-susceptibility procedure [34]. This procedure
includes the steps of agar plate inoculation, paper disk impregnation with an antibiotic
solution, and testing of the inhibitory effect of the impregnated disc when placed on the
inoculated plate. Each elution sample or standard solution was tested in triplicate.
All the elution solutions (collected at 0.5, 1, 3, 7, 14, and 21 days) showed a
strong inhibitory effect (Figures 6 and 7). The zones of inhibition are plotted either as a
function of release time (Fig. 6) or as a function of vancomycin concentration in solution
(Fig. 7). Figure 7 also shows the efficacy of released vancomycin in comparison to that of
standard vancomycin solutions. The zones of inhibition significantly exceeded the zone
of the MIC of vancomycin for S. aureus (4 µg/ml [32]). Focusing on the semilogarithmic plots in Figure 7, there is a linear relationship between the dimension of the

zone of inhibition and the vancomycin concentration for both solutions tested (the elution
solutions and the solutions with calibrated additions of vancomycin). The correlation
coefficients, r2, are equal to 0.995 and 0.999, respectively. This linear relationship is
expected in a disc susceptibility test [34]. The overlapping nature of the two sets of data
of Figure 7 suggests that the bactericidal efficacy of released vancomycin corresponds to
that of the vancomycin solution.
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Figure 6. Zone of S. aureus inhibition as a function of vancomycin elution time.
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Figure 7. Zone of inhibition of vancomycin released from silica xerogel versus that of standard
solutions.

These results provide strong evidence that vancomycin released from silica
xerogels fully retains its bactericidal properties. For all molecules studied, we have found
that sol-gel processing does not adversely affect the biological activity of molecules
incorporated into the xerogels.

In vivo compatibility and resorption behavior of silica xerogels
The tissue response to silica xerogels was determined in the sub-acute
implantation phase (up to 4 weeks of implantation) [26]. We correlated the findings to the
composition and the resorption rate of the various xerogels. Silica xerogels with and
without vancomycin were used .
All xerogels were synthesized by acid-catalyzed hydrolysis of TMOS. Xerogel
implants were shaped either as discs, 8 mm in diameter and 2 mm thick, or as granules in
the size range of 710-1000 µm. The materials were sterilized by γ-radiation.
Xerogel discs were implanted subcutaneously into the back of New Zealand
White rabbits. Additionally, granules were implanted into cylindrical defects (5 mm in
diameter and 2 mm in depth) created in the iliac crest. Experimental groups also included
controls (sham surgery without implant material). The samples with surrounding tissue
were retrieved after either 2 or 4 weeks of implantation. The tissue response was
analyzed on thin, stained sections using light microscopy. A total of 34 bone and 38
subcutaneous samples were used for the analysis.
Inflammatory response was scored using a scale from 0 to 4 (0: absent, 1:
minimal, 2: mild, 3: moderate, 4: severe) [7]. Morphometric measurements of bone

growth and granule size as a function of implantation time were made using a
semiautomatic image analysis system consisting of a high resolution color video camera
and Image-Pro Plus analysis software. Statistical analysis was performed using a twoway analysis of variance (ANOVA).
Histological analysis of tissue samples indicated that all subcutaneously
implanted discs were encapsulated by a pseudo-synovial membrane of densely packed
collagen fibers after 2 weeks of implantation. Xerogel discs showed a minimal
inflammatory response, after both 2 and 4 weeks of implantation (the score varied from
0.5 to 1.5).
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Figure 8. Mean surface area of xerogel granules as a function of implantation time.Error bars represent standard
deviation (n=9).

All granules implanted into bone defects showed a gradual decrease in size with
implantation time as the morphometric data illustrates in Figure 8. The granule resorption
produced a minimal inflammatory response (the score varied from 0.5 to 1.5). The score
was lower for granules with vancomycin than for those without it. This resorption was

accompanied by extensive trabecular bone ingrowth. As illustrated by light microscopy
microphotographs in Figures 9a and 9b, the bone ingrowth for both the control and the
xerogel groups was comparable. The trabecular growth was observed in close vicinity to
the granules. The trabeculae were covered with a layer of osteoid tissue and a row of
active osteoblasts. The healing of the bone defects via trabecular bone growth, evaluated
quantitatively as a ratio of new bone to defect area (Figure 10), was statistically the same
for the control and material-filled defects at both 2 and 4 weeks of implantation.

Figure 9 a, b. Micrographs of the bone defects after two weeks of implantation: (a) control and (b) defect with
implanted xerogel granules. Extensive trabecular bone ingrowth was observed for both the control and the
implant groups.
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Figure 10. Percent of new bone in the defect as a function of implantation time and experimental groups
(control and xerogel). Error bars represent standard deviation (n=9).

This study demonstrates a favorable tissue response to silica xerogels in both
subcutaneous and bone sites. Xerogel materials in a granular form showed a gradual
resorption, which was accompanied by extensive bone growth. Based on these
observations, controlled release silica xerogels are resorbable and biocompatible
materials.

Conclusion
Based on the in vitro and the in vivo analyses, silica xerogels can be characterized as
resorbable and biocompatible materials for the controlled release of drugs and larger
biologically active molecules.
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